Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Wisconsin: - Langlade Hospital and Cancer Center — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Ascension Saint Elizabeth Hospital — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Wisconsin: - Langlade Hospital and Cancer Center — Antigo, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
- Aurora Saint Luke's South Shore — Cudahy, Wisconsin
- Mayo Clinic Health System-Eau Claire Clinic — Eau Claire, Wisconsin
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Wisconsin: - Langlade Hospital and Cancer Center — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- ThedaCare Cancer Care - Berlin — Berlin, Wisconsin
- Mayo Clinic Health System-Eau Claire Clinic — Eau Claire, Wisconsin
- Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in Wisconsin: - Research Site — Appleton, Wisconsin
- Research Site — Madison, Wisconsin
- Research Site — Milwaukee, Wisconsin
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Wisconsin: - Research Site — Madison, Wisconsin
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Wisconsin: - Aurora BayCare Medical Center — Green Bay, Wisconsin
- Aurora St Lukes Medical Center — Milwaukee, Wisconsin
Phase 3 Recruiting Industry
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in Wisconsin: - University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040) — Madison, Wisconsin
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Wisconsin: - ThedaCare Regional Cancer Center — Appleton, Wisconsin
- ThedaCare Regional Medical Center - Appleton — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- ThedaCare Cancer Care - Berlin — Berlin, Wisconsin
- Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the reco…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05563220
Sites in Wisconsin: - University of WI - Carbone Cancer Center (Phase II only) — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups: * Cohort 1: Patients with ER+ / HER2- b…
Sponsor: Aminex Therapeutics, Inc.
NCT ID: NCT07287917
Sites in Wisconsin: - University of Wisconsin-Madison Carbone Cancer Center — Madison, Wisconsin
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as asses…
Sponsor: Criterium, Inc.
NCT ID: NCT05458674
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
In the phase I part, to determine the recommended doses (RD) and dosing regimens of \[177Lu\]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epi…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06247995
Sites in Wisconsin: - University Of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting Academic/Other
The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR)-positive metastatic breast cancer, and to determin…
Sponsor: University of Wisconsin, Madison
NCT ID: NCT04573231
Sites in Wisconsin: - University of Wisconsin School of Medicine and Public Health — Madison, Wisconsin
Phase 2 Recruiting Academic/Other
This clinical trial will investigate an estrogen-regulated parameter as an early measure of endocrine therapy response: progesterone receptor (PR) protein with a progestin-based radioligand, 18F-fluorofuranylnorprogesterone (18F-FFNP). The…
Sponsor: University of Wisconsin, Madison
NCT ID: NCT06086704
Sites in Wisconsin: - UW Carbone Cancer Center — Madison, Wisconsin
Phase 1 Recruiting Industry
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Sponsor: IDEAYA Biosciences
NCT ID: NCT05787587
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 1 Recruiting Industry
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is …
Sponsor: Eli Lilly and Company
NCT ID: NCT07213791
Sites in Wisconsin: - University of Wisconsin - Carbone Cancer Center — Madison, Wisconsin
Phase 1 Recruiting Industry
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT ID: NCT06625775
Sites in Wisconsin: - Wisconsin Institute for Medical Research — Madison, Wisconsin
Phase 1 Recruiting Industry
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapi…
Sponsor: Incyte Corporation
NCT ID: NCT05238922
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
EARLY Phase 1 Recruiting Academic/Other
Despite broad advancements in endocrine therapy for ERα+ breast cancer, resistance ultimately develops. A common driver of resistance are known ESR1 mutations that lead to constitutively active receptor signaling and transcriptional regula…
Sponsor: University of Wisconsin, Madison
NCT ID: NCT04174352
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
- Wisconsin Oncology Network (WONIX) sites — Madison, Wisconsin
NA Recruiting Network
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to e…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06112613
Sites in Wisconsin: - ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Ascension Saint Elizabeth Hospital — Appleton, Wisconsin
- ThedaCare Cancer Care - Berlin — Berlin, Wisconsin
- Ascension Southeast Wisconsin Hospital - Elmbrook Campus — Brookfield, Wisconsin
- Ascension Calumet Hospital — Chilton, Wisconsin
Phase 4 Recruiting Industry
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x…
Sponsor: Guerbet
NCT ID: NCT04373564
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Recruiting Industry
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find the…
Sponsor: Tempus AI
NCT ID: NCT07211178
Sites in Wisconsin: - Gunderson Health — La Crosse, Wisconsin
NA Recruiting Academic/Other
Very little is understood about the off-target vascular mechanisms of anti-cancer drug toxicity and the impact of exercise on these changes. Much of what has been learned about molecular pathways regulating vascular endothelial function ha…
Sponsor: Medical College of Wisconsin
NCT ID: NCT05223322
Sites in Wisconsin: - Medical College of Wisconsin — Wauwatosa, Wisconsin
NA Recruiting Academic/Other
This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB). 50 participants will…
Sponsor: University of Wisconsin, Madison
NCT ID: NCT06295744
Sites in Wisconsin: - UW Carbone Cancer Center — Madison, Wisconsin
NA Recruiting Academic/Other
This single-arm study is designed to test the hypothesis that a six-month intermittent fasting (IF) intervention is feasible for patients to adhere to and improves health-related quality of life while subjects are on adjuvant endocrine the…
Sponsor: Medical College of Wisconsin
NCT ID: NCT06106477
Sites in Wisconsin: - Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin